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Abstract 
Context 
Practice patterns for the management of urinary retention (UR) secondary to benign prostatic 
obstruction (BPO; UR/BPO) vary widely and remain unstandardized. 
Objective 
To review the evidence for managing patients with UR/BPO with pharmacological and 
nonpharmacological treatments included in the European Association of Urology guidelines on 
non-neurogenic male lower urinary tract symptoms. 
Evidence acquisition 
Search was conducted up to April 22, 2018, using CENTRAL, MEDLINE, Embase, 
ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform. 
This systematic review included randomized controlled trials (RCTs) and prospective 
comparative studies. Methods as detailed in the Cochrane handbook were followed. Certainty of 
evidence (CoE) was assessed using the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) approach. 
Evidence synthesis 
Literature search identified 2074 citations. Twenty-one studies were included (qualitative 
synthesis). The evidence for managing patients with UR/BPO with pharmacological or 
nonpharmacological treatments is limited. CoE for most outcomes was low/very low. Only α1-
blockers (alfuzosin and tamsulosin) have been evaluated in more than one RCT. Pooled results 
indicated that α1-blockers provided significantly higher rates of successful trial without catheter 
compared with placebo [alfuzosin: 322/540 (60%) vs 156/400 (39%) (odds ratio {OR} 2.28, 95% 
confidence interval {CI} 1.55 to 3.36; participants = 940; studies = 7; I2 = 41%; low CoE); 
tamsulosin: 75/158 (47%) vs 40/139 (29%) (OR 2.40, 95% CI 1.29 to 4.45; participants = 297; 
studies = 3; I2 = 30%; low CoE)] with rare adverse events. Similar rates were achieved with 
tamsulosin or alfuzosin [51/87 (59%) vs 45/84 (54%) (OR 1.28, 95% CI 0.68 to 2.41; participants 
= 171; studies = 2; I2 = 0%; very low CoE)]. Nonpharmacological treatments have been evaluated 
in RCTs/prospective comparative studies only sporadically. 
Conclusions 
There is some evidence that usage of α1-blockers (alfuzosin and tamsulosin) may improve 
resolution of UR/BPO. As most nonpharmacological treatments have not been evaluated in 
patients with UR/BPO, the evidence is inconclusive about their benefits and harms. 
Patient summary 
There is some evidence that alfuzosin and tamsulosin may increase the rates of successful trial 
without catheter, but little or no evidence on various nonpharmacological treatment options for 
managing patients with urinary retention secondary to benign prostatic obstruction. 
Keywords: 
Benign prostatic obstruction, Meta-analysis, Prostate, Randomized controlled trial, Treatment 
outcome, Urinary retention  
1. Introduction 
Urinary retention (UR) is the inability of a patient to completely or partially empty the bladder by 
voluntary micturition. UR can be acute or chronic. Acute UR (AUR) is defined as a painful, 
palpable, or percussible bladder, when the patient is unable to pass any urine [1, 2]. Chronic UR 
(CUR) is defined as a nonpainful bladder, which remains palpable or percussible after the patient 
has passed urine [1, 2]. The term implies a significant postvoid residual urine volume (PVR); a 
minimum figure of 300 ml has been mentioned [1, 2]. Nevertheless, the exact definitions of AUR 
and CUR remain controversial [3]. The exact incidence of UR in the general population remains 
unclear, with various estimates suggested from 2.2 to 6.8 events/1000 patient-years [4, 5]. 
Benign prostatic obstruction (BPO) is considered the most prevalent cause of UR in men [5]. 
Several α1-adrenoceptor antagonists (α1-blockers) have been tested in patients with AUR to 
increase the rates of successful trial without catheter (TWOC), including alfuzosin [6, 7, 8], 
tamsulosin [6, 9], and silodosin [10], most of which demonstrate a higher success rate than 
placebo. The alfuzosin in AUR (ALFAUR) study, the largest clinical trial to date, evaluated the 
role of alfuzosin 10 mg once daily (OD) administrated 2–3 d before TWOC and showed that 
alfuzosin almost doubled the successful TWOC rate [11]. Since most patients having a 
successful TWOC have no AUR relapse in the short term, administration of an α1-blocker before 
catheter withdrawal is considered a valuable treatment [12]. It has been reported that >80% of 
patients who did not receive any treatment after an AUR episode were submitted to surgery 
within 5 yr [13]. As a result, pharmacological intervention should be considered not only an aid to 
increase the chance of successful TWOC, but also a mean to reduce AUR recurrence risk, which 
could lead to further interventions in the long term. Data from five studies, which evaluated the 
long-term use of α1-blockers, showed that patients receiving α1-blockers had a significantly 
lower risk of recurrent AUR [14]. The use of 5α reductase inhibitors (5ARIs) as a combination 
therapy with α1-blockers in AUR treatment is still controversial [15, 16]. Urgent prostatic surgery 
is another therapeutic option for AUR, however with a higher risk of intra- and/or postoperative 
complications and mortality than elective surgery [17]. Therefore, elective surgery is the 
treatment of choice for most men who fail TWOC. Increased perioperative morbidity is also 
associated with the presence of an indwelling urinary catheter in cases operated after TWOC 
failure [18]. 
Management of UR secondary to BPO (UR/BPO) varies widely. Relevant systematic reviews 
(SRs) are scarce [19, 20, 21]. The European Association of Urology (EAU) Non-neurogenic Male 
Lower Urinary Tract Symptoms (LUTS) Guidelines Panel acknowledges the current lack of high 
certainty of evidence (CoE) and the growing scientific base, and cites the need to understand 
more about management options. This SR is a product of this panel and compared the 
effectiveness of various treatment options currently available for patients with UR/BPO. The 
objective was to address the following questions: 
• 1. 
What are the benefits of treatments for UR (AUR or CUR) in adults with BPO? 
• 2. 
What are the harms of treatments for UR (AUR or CUR) in adults with BPO? 
  
2. Evidence acquisition 
Randomized controlled trials (RCTs), quasi-RCTs (QRCTs), and prospective comparative 
studies were included. Any other studies, such as noncomparative studies, retrospective studies, 
and case series, were excluded. Studies were included only if the following conditions were met: 
• 1. 
UR (AUR or CUR)/BPO was addressed as a study outcome. 
• 2. 
A subanalysis (or post hoc analysis) of participants presenting with UR (AUR or CUR)/BPO 
was reported. 
• 3. 
Pharmacological treatment had been evaluated in an RCT or QRCT setting. 
• 4. 
Nonpharmacological treatment had been evaluated in an RCT, QRCT, or prospective 
comparative study setting. 
• 5. 
At least one of the primary or secondary outcomes of this SR was reported. 
Adult men (≥18 yr) with UR (AUR or CUR defined as a persistently elevated PVR of ≥300 ml) 
secondary to BPO were included. Individuals with UR attributed to drug side effects, 
pharmacological/nonpharmacological procedures, suspected or confirmed urethral/bladder 
pathology (such as malignancy, urethral stricture, bladder neck contracture, bladder stones, 
neurogenic bladder, and infection/inflammation), or prostate cancer were excluded. 
The following comparisons of intervention versus comparator were investigated: 
• Intervention: 
Any pharmacological or nonpharmacological treatment included in the EAU guidelines on 
non-neurogenic male LUTS (2018), as defined below: 
o 1. 
Pharmacological treatment (monotherapy or combination therapy): α1-blockers, 
5ARIs, phosphodiesterase 5 inhibitors (PDE5Is), plant extracts (phytotherapy). 
o 2. 
Nonpharmacological treatment: any kind of instrumental intervention (surgical 
treatment, such as transurethral resection of the prostate [TURP]), including 
suprapubic catheterization (SPC) or urethral catheterization irrespective of duration 
prior to TWOC. 
o 3. 
Any combination of the above pharmacological and nonpharmacological treatments. 
• Comparator: 
• 1. 
No treatment. 
• 2. 
Placebo or sham treatment. 
• 3. 
Any pharmacological or nonpharmacological treatment, as defined above (any comparison 
within intervention was accepted, such as comparison of different pharmacological 
treatments and/or comparison of different types of catheterization). 
We performed a broad search of the Core Outcome Measures in Effectiveness Trials (COMET) 
database (http://www.comet-initiative.org/) for a core outcome set (COS) using the term “urology” 
in the disease category. No directly applicable COS existed for the disease or treatments dealt in 
this SR. Therefore, the EAU Guidelines Panel reached consensus on what they regarded as 
most important outcomes for this condition. No patient advocates or other stakeholders were 
involved in the consensus process. 
The primary benefit outcomes were the following: 
• 1. 
Successful TWOC rate as defined by trials in each single study. 
• 2. 
UR (AUR or CUR) recurrence rate following a successful TWOC. 
The primary harm outcomes were as follows: 
• 1. 
Harms of treatment for UR (AUR or CUR) including any adverse effects reported (such as 
death, pharmacological/nonpharmacological treatment complications). Surgical 
complications occurring up to 1 mo postoperatively, which were specifically graded 
according to the modified Clavien classification system [22, 23]. 
The secondary outcomes included the following: 
• 1. 
Maximum flow rate (Qmax), International Prostate Symptom Score (IPSS) questionnaire 
results (including quality of life [QoL] score), PVR; absolute values and changes from 
baseline at each follow-up time point. 
• 2. 
Specific measures for evaluating nonpharmacological treatment (operation duration, 
bladder irrigation duration, postoperative catheterization, and hospitalization duration). 
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
approach was used to assess CoE for each comparison [24]. CoE of outcomes considered 
critical/important in decision making from patients’ perspective was rated based on study design, 
limitations in study design/execution (risk of bias [RoB]), inconsistency of results, indirectness of 
evidence, imprecision, and publication bias. Final decision on the selection of the outcomes to be 
rated was based on a consensus among the SR authors. We used the GRADEpro Guideline 
Development Tool to assess the CoE of the critical and important outcomes. Summary of 
findings (SoF) tables are available in the Supplementary material, and the following outcomes 
were chosen, listed according to priority: 
• 1. 
Successful TWOC rate (at 1 mo after the intervention). 
• 2. 
Modified Clavien classification system grade ≥3 (at 1 mo after the intervention). 
• 3. 
UR (AUR or CUR) necessitating additional pharmacological or nonpharmacological 
intervention rate following successful TWOC (at 12 mo after the intervention). 
• 4. 
IPSS score (at 12 mo after the intervention). 
• 5. 
QoL score (at 12 mo after the intervention). 
The literature was systematically searched in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement [25, 26]. We followed the 
methodology as detailed in the Cochrane handbook for systematic reviews of interventions [27]. 
Search strategies are available in the Supplementary material. 
The following electronic databases were searched up to April 22, 2018: 
• 1. 
The Cochrane library databases (Cochrane Central Register of Controlled Trials [March 
2018], Cochrane Database of Systematic Reviews [2005 to April 18, 2018]). 
• 2. 
Medline (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R) [1946 to April 2018]). 
• 3. 
Embase (OvidSP [1974 to April 2018]). 
Hand searches of the following trial registers/websites were also performed: 
• 1. 
ClinicalTrials.gov (https://clinicaltrials.gov/). 
• 2. 
World Health Organization International Clinical Trials Registry Platform 
(http://www.who.int/ictrp/en/). 
• 3. 
For new(er) pharmacological compounds manufacturers’ websites, Food and Drug 
Administration and European Medicines Agency websites were searched (no restriction on 
date of publication). 
Other potentially eligible studies were searched for using reference lists of included studies, other 
SRs, or health technology assessment reports. Search was supplemented by manually 
searching the reference list of the EAU guidelines on non-neurogenic male LUTS. 
Two review authors (M.K. and I.K.) independently scanned the title or the abstract content, or 
both, of every record retrieved to determine which studies should be assessed further; extracted 
all data; and assessed RoB of each included study. Any disagreements were resolved through 
consensus or by consultation with a third author (C.M.). RoB in RCTs was assessed using the 
Cochrane “RoB” assessment tool [27, 28]. “RoB” domains were judged as low, high, or unclear 
risk [27]. RoB in nonrandomized comparative studies was assessed using all the domains of 
Cochrane RoB tools [29]. In addition, a list of the six most important potential confounders for 
harm and benefit outcomes were developed a priori with clinical content experts (EAU Guidelines 
Panel on Non-neurogenic Male LUTS): (1) age, (2) severity of LUTS (IPSS score), (3) prostate 
volume, (4) active and previous medical treatment for BPO, (5) prior history of UR, and (6) 
history of prostatic infection. When at least two included trials were available for comparison of a 
given binary/dichotomous/categorical benefit or harm outcome, data were expressed as odds 
ratio (OR) with 95% confidence interval (CI) and p value where available. For continuous 
outcomes measured on the same scale, the intervention effect was estimated using mean 
difference (95% CI). Meta-analysis was performed where more than one RCT reported the same 
outcome. In the event of substantial clinical/methodological heterogeneity, trial results were not 
reported as pooled effect estimate. Heterogeneity was identified by visually inspecting forest 
plots and by using a standard chi-square test with a significance level of α = 0.1. In view of the 
low power of this test, I2 statistic was also considered, which quantifies inconsistency across trials 
to assess heterogeneity impact on the meta-analysis [30]. Heterogeneity was dealt as suggested 
in the Cochrane handbook for systematic reviews of interventions [27]. 
The protocol of the present SR was published on PROSPERO (Supplementary material).  
3. Evidence synthesis 
A total of 21 studies (18 RCTs [6, 7, 8, 9, 10, 11, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42] 
and three prospective comparative studies [43, 44, 45]) were included. Fig. 1 illustrates the 
literature flow. Table 1 presents baseline characteristics of included studies. RoB assessment is 
illustrated in Fig. 2. 
 
Fig. 1 
PRISMA flow diagram. Citations in conference abstract form and those written in non-English 
language were excluded. EAU = European Association of Urology; PRISMA = Preferred 
Reporting Items for Systematic Reviews and Meta-analyses; UR = urinary retention; BPO = 
benign prostatic obstruction. 
 
Table 1Baseline characteristics of included studies 
Study 
Compa
rison 
Desi
gn 
N
o. 
of 
pt
s 
F
U 
(m
o) 
Age 
(yr), 
mean 
(SD) 
IPS
S 
Prostat
e 
volume, 
mean 
(SD) 
Histo
ry of 
medic
al 
treat
ment 
Hist
ory 
of 
UR 
Histo
ry of 
prost
atic 
infec
tion 
Agraw
al 
(2009) 
[6] 
Alfuzosin 
10 mg vs 
tamsulosin 
0.4 mg vs 
placebo 
RCT 15
0 
3 
mo 
Alfuzosin: 
69.4 (8.8); 
tamsulosin: 
72.2 (8.5) 
NR NR NR 0 0 
Al-
Hashi
mi 
(2007) 
[31] 
Alfuzosin 
10 mg vs 
placebo 
RCT 22
4 
3 d NR NR 65 (100) NR 0 NR 
Hassan 
(2018) 
[32] 
Tamsulosi
n 0.4 mg 
OD for 3 d 
vs 
tamsulosin 
0.4 mg OD 
for 7 d 
RCT 60 1.5 59.2 (8.0) 13.3 
(3.9) 
61.5 (23.1) 0 0 NR 
     
60.5 (9.7) 13.2 
(3.3) 
57.9 (25.0) 
   
Kara 
(2014) 
[33] 
Tamsulosi
n 0,4 mg 
vs 
tamsulosin 
+ alfuzosin 
10 mg OD 
RCT 70 9 71.2 NR NR NR NR NR 
Kumar 
(2013) 
[10] 
Silodosin 8 
mg OD vs 
placebo 
RCT 60 3 d Silodosin: 
64.5 (9.3); 
placebo: 
65.8 (8.1) 
Silod
osin: 
25.7 
(2.5); 
place
bo: 
26.6 
(2.1) 
Silodosin: 
42.3 (7.9); 
placebo: 
44.5 (9.6) 
NR NR NR 
Lucas 
(2005) 
[9] 
Tamsulosi
n 0.4 mg 
vs placebo 
RCT 14
1 
6.5 69.4 NR NR NR NR NR 
Maldo
nado-
Avila 
(2014) 
[34] 
Tamsulosi
n 0.4 mg 
vs 
alfuzosin 
10 mg vs 
placebo 
RCT 90 5 d Tamsulosin
: 65.2 (9.1); 
alfuzosin: 
63.6 (8.9) 
NR NR NR NR NR 
McNeil 
(1999) 
[7] 
Alfuzosin 
5 mg bd vs 
placebo 
RCT 80 Ope
n 
Alfuzosin: 
67.7 (13.6); 
placebo: 
72.7 (8.33) 
NR NR NR NR NR 
McNeil
l (2004) 
[11] 
Alfuzosin 
10 mg OD 
vs placebo 
RCT 35
7 
6 69.3 (8.3) NR NR NR 0 10 
Patil 
(2017) 
[35] 
Tamsulosi
n 0.4 mg 
vs 
silodosin 8 
mg 
RCT 16
0 
1 Tamsulosin
: 64.5 (9.3); 
silodosin: 
65.8 (8.1) 
NR Tamsulosin
: 42.3 (7.0); 
silodosin: 
44.5 (9.6) 
NR 0 NR 
Prieto 
(2008) 
[36] 
Doxazosin 
4 mg vs no 
medication 
RCT 46 24 74.4 (8.4) NR Doxazosin: 
61.2 (30); 
no 
medication: 
58.7 (25) 
0 0 0 
Shah 
(2002) 
[8] 
Alfuzosin 
5 mg bd vs 
placebo 
RCT 62 24 Alfuzosin: 
69.5; 
placebo: 
67.7 
NR NR 0 NR 0 
Sharifi 
(2014) 
[37] 
Tamsulosi
n 0.4 mg + 
sildenafil 
50 mg vs 
tamsulosin 
+ placebo 
RCT 10
1 
3 Tamsulosin 
+ 
sildenafil: 
59.6 (3.8); 
tamsulosin 
+ placebo: 
60.6 (4.1) 
NR Tamsulosin 
+ 
sildenafil: 
54.9 (19.2); 
tamsulosin 
+ placebo: 
52.7 (15.5) 
0 0 0 
Tiong 
(2009) 
[38] 
Alfuzosin 
10 mg vs 
placebo 
RCT 64 2d Alfuzosin: 
72.5 (10.3); 
placebo: 
71.9 (9.4) 
Alfuz
osin: 
16.3 
(8.7); 
place
bo: 18 
(8.5) 
NR 0 0 NR 
Ghalay
ini 
(2005) 
[39] 
TURP vs 
CIC before 
TURP 
RCT 41 6 TURP: 67 
(8); CIC: 
69 (7.3) 
TURP
: 25.8 
(4.2); 
CIC: 
23.2 
(6.1) 
NR NR NR NR 
Guazzo
ni 
(1993) 
[43] 
Prostatic 
spiral vs 
prostatic 
stent 
Prospe
ctive 
compar
ative 
38 12 Spiral: 85; 
stent: 81 
NR NR NR NR NR 
Horgan 
(1992) 
[44] 
Urethral 
catheteriza
tion vs 
SPC 
Prospe
ctive 
compar
ative 
86 36 NR NR NR NR NR NR 
Mamo
ulakis 
(2013) 
[40, 47] 
M-TURP 
vs B-
TURP 
RCT 11
3 
36 M-TURP: 
70.4 (9.5); 
B-TURP: 
72.2 (8.6) 
NR M-TURP: 
69.5 (37.2); 
B-TURP: 
72.6 (35.7) 
0 NR 0 
Patel 
(2001) 
[45] 
CIC vs 
indwelling 
catheteriza
tion 
Prospe
ctive 
compar
ative 
50 NR CIC: 69; 
Indwelling 
catheter: 71 
NR NR NR NR NR 
Schelin 
(2006) 
[41] 
TUMT vs 
TURP/enu
cleation 
RCT 12
0 
6 TUMT: 73; 
TURP/enuc
leation: 73 
NR TUMT: 
71.6; 
TURP/enuc
leation: 
66.8 
NR NR NR 
Zhengy
ong 
(2014) 
[42] 
BT vs no 
BT 
RCT 84
5 
 
66 BT: 
19 
(6.9); 
no 
BT: 
20 
(7.9) 
BT: 52 
(12.4); No 
BT: 53 
(12.7) 
NR 0 0 
View Table in HTML 
BT = bladder training; B-TURP = bipolar TURP; M-TURP = monopolar TURP; CIC = clean 
intermittent catheterization; IPSS = International Prostate Symptom Score; NR = not reported; 
OD = once daily; pt = patients; RCT = randomized controlled trial; SD = standard deviation; SPC 
= suprapubic catheterization; TUMT = transurethral microwave thermotherapy; TURP = 
transurethral resection of the prostate; UR = urinary retention. 
 
Fig. 2 
Risk of bias assessment of included studies (red: high risk of bias; yellow: unclear risk of bias; 
green: low risk of bias): (A) RCTs and (B) non-RCTs (prospective comparative studies). BPO = 
benign prostatic obstruction; IPSS = International Prostate Symptom Score; RCT = randomized 
controlled trial; UR = urinary retention. 
3.1. Pharmacological treatments 
Among the pharmacological treatments included in the EAU guidelines on non-neurogenic male 
LUTS, only α1-blockers (alfuzosin, tamsulosin, silodosin, and doxazosin) and the PDE5I 
sildenafil have been evaluated for treating patients with UR/BPO in RCTs. No RCT addressing 
results on any other pharmacological treatment (monotherapy or combination therapy) included 
in the EAU guidelines on non-neurogenic male LUTS, such as 5ARIs (finasteride and 
dutasteride), was detected. 
Alfuzosin was compared with placebo in seven RCTs [6, 7, 8, 11, 31, 34, 38]. Pooled results 
indicated that alfuzosin provided significantly higher successful TWOC rates than placebo 
(322/540 [60%] vs 156/400 [39%]; OR 2.28, 95% CI 1.55 to 3.36; participants = 940; studies = 
7; I2 = 41%; low CoE; Fig. 3). Adverse events, most commonly including dizziness, headache, 
and orthostatic hypotension, were generally rare, without any difference between arms. 
Tamsulosin was compared with placebo in three RCTs [6, 9, 34]. In two of them, patients were 
randomized to three arms (tamsulosin vs alfuzosin vs placebo) [6, 34]. Pooled results indicated 
that tamsulosin provided significantly higher successful TWOC rates than placebo (75/158 [47%] 
vs 40/139 [29%]; OR 2.40, 95% CI 1.29 to 4.45; participants = 297; studies = 3; I2 = 30%; low 
CoE; Fig. 4) but similar rates to alfuzosin (51/87 [59%] vs 45/84 [54%]; OR 1.28, 95% CI 0.68 to 
2.41; participants = 171; studies = 2; I2 = 0%; very low CoE). Tamsulosin was also compared with 
tamsulosin/alfuzosin combination in one RCT [33] and tamsulosin/sildenafil combination in 
another RCT [37]. No difference between monotherapy and tamsulosin/alfuzosin combination 
was detected regarding successful TWOC rates: 11/35 (31%) versus 14/35 (40%); OR 0.69, 95% 
CI 0.26 to 1.84; participants = 70; studies = 1; very low CoE. Most common adverse events in the 
combination arm included dizziness, headache, and retrograde ejaculation, which were not 
significantly higher than those in the monotherapy arm [33]. The tamsulosin/sildenafil 
combination was also similar to monotherapy regarding successful TWOC rates: 41/50 (82%) 
versus 37/51 (73%); OR 1.46, 95% CI 0.66 to 3.25; participants = 101; studies = 1; very low CoE 
[37]. Three-day versus 7-d tamsulosin treatment for AUR was compared in one RCT [32]. No 
significant difference was observed in successful TWOC rates: 18/30 (60%) versus 21/30 (70%); 
OR 0.64, 95% CI 0.22 to 1.87; participants = 60; studies = 1; very low CoE. Silodosin was 
compared with placebo in one RCT, showing a significantly higher successful TWOC rate at 3 d: 
23/30 (77%) versus 11/30 (37%); OR 5.68, 95% CI 1.84 to 17.5; participants = 60; studies = 1; 
very low CoE [10]. Silodosin was also compared with tamsulosin in one RCT showing no 
significant differences in successful TWOC rates: 48/80 (60%) vs 54/80 (68%); OR 1.44, 95% CI 
0.76 to 2.71; participants = 160; studies = 1; very low CoE or complication rates between arms 
[35]. Doxazosin was compared with no medication in one RCT showing no difference in 
successful TWOC rates: 13/22 (59%) versus 13/24 (54%); OR 1.22, 95% CI 0.38 to 3.93; 
participants = 46; studies = 1; very low CoE [36]. 
 
Fig. 3 
Alfuzosin versus placebo; successful TWOC rate at TWOC. CI = confidence interval; M-H = 
Mantel-Haenszel; TWOC = trial without catheter. 
 
Fig. 4 
Tamsulosin versus placebo; successful TWOC rate at TWOC. CI = confidence interval; M-H = 
Mantel-Haenszel; TWOC = trial without catheter. 
3.2. Nonpharmacological treatments 
Very few nonpharmacological treatment options included in the EAU guidelines on the 
management of non-neurogenic male LUTS have been evaluated for managing patients with 
UR/BPO in RCTs/prospective comparative studies. None of them has been evaluated in more 
than one trial. An international multicenter RCT evaluated bipolar TURP (B-TURP) versus 
monopolar TURP (M-TURP) in 279 patients with BPO [40, 46, 47, 48]. A subanalysis [46, 47] 
and post hoc analysis (Supplementary Tables 1–3) on patients presenting with UR (B-TURP: n = 
50; M-TURP: n = 63) revealed no difference between arms either for successful TWOC rates: 
47/50 (94%) vs 57/63 (90%); OR 1.65, 95% CI 0.39 to 6.95; participants = 113; studies = 1; low 
CoE or for any of the outcomes of interest of this SR. In an RCT comparing transurethral 
microwave thermotherapy (TUMT) with TURP or open prostatectomy in patients with UR, no 
difference was detected in successful TWOC rates between arms: 48/61 (79%) versus 52/59 
(88%); OR 0.58, 95% CI 0.22 to 1.52; participants = 120; studies = 1; very low CoE [41]. More 
complications were seen in TURP/enucleation arm. In one RCT, the efficacy of bladder training 
before catheter removal was evaluated in patients with a first episode of AUR secondary to BPO 
randomized to pharmacological treatment (combination of tamsulosin 0.2 mg/finasteride 5 mg 
OD) with free catheter drainage for 7 d (n = 405) or pharmacological treatment combined with 
bladder training (n = 440) prior to TWOC [42]. Similar successful TWOC rates (190/405 [47%] vs 
187/440 [43%]; OR 0.84, 95% CI 0.64 to 1.10; participants = 840; studies = 1; moderate CoE) 
and adverse event rates were observed in both arms. Transurethral catheterization versus SPC 
in patients with AUR was assessed in a prospective comparative study [44]. Thirty patients 
received transurethral catheterization and 56 patients received SPC (12F Cystofix). Patients 
were followed up for 3 yr. TWOC failure was observed in seven out of 11 patients (64%) in the 
transurethral group versus seven out of 22 patients (32%) in the SPC group. Complication rates 
were notably higher in the transurethral group (urinary tract infections [UTIs]: 12 out of 30 
patients [40%] vs 10 out of 56 patients [18%], and urethral strictures: five out of 30 patients [17%] 
vs none out of 56 patients [0.0%]). Dislodgment was the only complication repeatedly associated 
with SPC: 13 patients (23%; 11 of these patients needed catheter replacement) versus one 
patient (3.4%), potentially necessitating a more secure form of catheter fixation such as a Foley 
catheter placement through a suprapubic introducer. Finally, our search criteria revealed an old 
study from 1993 comparing prostatic spiral (Uromed) with prostatic stent (Urolume) regarding 
effectiveness and complications [43]. Detailed results are available in the Supplementary 
material. SoF tables summarizing CoE assessment based on the GRADE approach are available 
in the Supplementary material.  
4. Discussion 
The evidence for managing patients with UR/BPO with pharmacological or nonpharmacological 
treatments is limited. CoE for most outcomes was low or very low. All selective α1-blockers 
(alfuzosin, tamsulosin, and silodosin) appear to be superior to placebo in terms of successful 
TWOC rates after a short period of catheterization [6, 7, 9, 10, 11, 31, 34, 38]. In contrast, no 
benefit has been revealed with the use of the nonselective α1-blocker doxazosin, and addition of 
sildenafil to tamsulosin does not offer additional benefit compared with tamsulosin monotherapy. 
However, these studies are underpowered; CoE is very low and therefore no definite conclusions 
can be drawn for these comparisons [36, 37]. Pooled results indicate that alfuzosin and 
tamsulosin monotherapy provide significantly higher successful TWOC rates than placebo with 
rare adverse events. Similar successful TWOC rates are achieved with alfuzosin or tamsulosin. 
Nonpharmacological treatments have been evaluated in RCTs/prospective comparative studies 
only sporadically. 
B-TURP and TUMT have both been tested against M-TURP and found to have comparable 
efficacy/safety for the management of patients with UR according to the authors of these studies 
[40, 41, 46, 47, 48], but this conclusion should be interpreted with caution. SPC appears to 
safeguard against some of the potential complications of urethral catheterization such as UTI and 
urethral stenosis, allowing assessment of spontaneous voiding and avoiding recatheterization 
after a failed attempt [44]. Although it has been suggested that SPC might be associated with 
lower rates of UTI and urethral stricture formation, less patient discomfort, and easier 
management, a Cochrane SR failed to demonstrate a lower risk of symptomatic UTIs with use of 
SPC [49]. A 3-d rather than a 7-d period of catheterization after a first episode of AUR in addition 
to α1-blocker treatment should be preferred, since longer catheterization time increases 
complication rates without significantly increasing TWOC success [32]. A short period of 
intermittent self-catheterization might be beneficial to maximize recovery of bladder function 
before TURP and should be preferred to indwelling catheterization in case of delayed surgery, as 
it is associated with fewer infectious complications [32, 36]. 
An SR on the management of AUR, including pharmacological and nonpharmacological 
treatment options, recommended the use of α1-blockers before TWOC, discouraging emergency 
operative management [21]. SPC over indwelling catheter use was debatable and catheterization 
duration was controversial, but <3 d appeared to be a safe option in avoiding catheterization-
related complications [21]. Although TURP remained the gold standard, there was emergence of 
newer operative management utilizing laser techniques [21]. Nevertheless, conclusions were 
limited due to low CoE [21]. 
In another SR, the effectiveness and comparative effectiveness of pharmacological and 
nonpharmacological treatments for CUR were evaluated [19]. A total of 11 studies (RCTs and 
prospective cohort studies) enrolling patients with CUR were included. Results were analyzed by 
etiology: obstructive, nonobstructive, and mixed populations/unknown causes. Only three studies 
addressed obstructive causes of CUR. Low-quality evidence suggested that TURP and TUMT 
achieved similar improvements in successful TWOC rates at 6 mo after treatment. Evidence was 
insufficient to draw conclusions regarding other outcomes. Evidence for other treatment 
comparisons for CUR from obstructive causes was insufficient to conclude that one treatment 
was more effective than the others. Evidence on harms was inconsistently reported across all 
interventions, and no differences were detected across treatment groups; however, studies were 
not adequately powered to detect differences in harms across groups. Further studies of patients 
with CUR are needed. 
A Cochrane SR assessed the effectiveness of α1-blockers in successful resumption of 
micturition following removal of urethral catheter after an episode of AUR in men [20]. Nine RCTs 
were included. There was moderate CoE to suggest that successful TWOC rates favored α1-
blockers over placebo. The incidence of recurrent AUR was lower in groups treated with α1-
blockers. CoE was moderate favoring alfuzosin, tamsulosin, and silodosin, but not doxazosin. Of 
the trials mentioning adverse effects, there was not enough information to detect statistically 
significant differences between groups and CoE was low. Overall, adverse effect rates were low 
for both placebo and α1-blockers [20].  
4.1. Strengths and limitations of this SR 
The major strengths are as follows: 
• 1. 
Performed a comprehensive literature search. 
• 2. 
Adopted a robust/transparent methodological approach based on Cochrane handbook. 
• 3. 
Assessed CoE with the GRADE approach. 
The principal limitations are the following: 
• 1. 
Although every effort was made following strict/specific trial exclusion criteria to exclusively 
include trials summarizing results from individuals with UR/BPO, the slight possibility of 
including few patients with neurological/bowel condition – or detrusor underactivity-
associated UR or even few patients without (urodynamically proven) BPO cannot be 
completely ruled out since raw individual patient data were not accessible. 
• 2. 
There was significant heterogeneity among identified studies. 
• 3. 
Included studies had a relatively small number of participants, short follow-up, and 
methodological flaws with inadequate reporting. Although authors were contacted for 
information whenever needed, the majority did not reply. Therefore, following the 
guidelines of the Cochrane handbook, many RoB domains were judged as unclear, that is, 
providing insufficient information to permit judgment.  
4.2. Recommendations for future research 
Future studies should consider the following recommendations: 
• 1. 
Several contemporary nonpharmacological treatment options included in the EAU 
guidelines on the management of non-neurogenic male LUTS were not assessed in this 
SR based on the inclusion criteria. For example, no comparative studies evaluating 
holmium, Greenlight, or thulium laser were detected. This represents a significant gap in 
the literature. Such a lack of evidence needs to be addressed by future studies since the 
subpopulation of UR patients is unique, harvesting specific perioperative risk factors. 
• 2. 
Further studies on CUR as well as on 5ARIs after successful TWOC would be logical—as 
these, and not α1-blockers, have been shown to reduce AUR rates. 
• 3. 
Previous UR is a well-established risk factor for ongoing AUR episodes. Older data 
indicated that only 16% of patients presenting with UR had remained catheter free for a 
period of 5 yr [13]. According to the EAU guidelines on the management of non-neurogenic 
male LUTS, surgical treatment is usually required when patients have experienced, among 
others, recurrent/refractory UR or overflow incontinence (absolute operation indication, 
need for surgery) [50]. Nevertheless, future studies that will help reliably identify patients 
who could respond to prolonged medical treatment and who should be scheduled for 
prompt or elective surgery are deemed necessary. 
• 4. 
Optimum treatment management for frail patients with significant comorbidities in the long 
term remains poorly documented, at least with respect to the studies directly comparing 
different treatment modalities (eg, surgery vs long-term catheterization). Future research 
should focus on this area. 
• 5. 
The observed heterogeneity of TWOC success definitions among studies not only has an 
important impact on the assessment of treatment outcomes, but also renders adoption of a 
universally accepted definition of TWOC success necessary in future studies. 
• 6. 
COS should be developed for UR/BPO, by following the COMET initiative. 
• 7. 
Future studies should be adequately powered or should follow the 
principle/recommendation of Consolidated Standards of Reporting Trials (CONSORT) 
statement.  
5. Conclusions 
The evidence for managing patients with UR/BPO with pharmacological or nonpharmacological 
treatments is limited. CoE is generally low. There is some evidence that usage of α1-blockers 
(alfuzosin and tamsulosin) may improve resolution of UR/BPO. As most nonpharmacological 
treatments have not been evaluated in patients with UR/BPO, the evidence is inconclusive about 
their benefits and harms. 
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